Full Press Release Details
SAN FRANCISCO,April 28, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq:NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website:https://ir.nektar.com/.The web broadcast of the conference call will be available for replay through June 7, 2026.
To access the conference call, please pre-register atNektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
AboutNektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visitwww.nektar.comand follow us onLinkedIn.
For Investors:
Vivian Wu628-895-0661[email protected]
Corey Davis, Ph.D.LifeSci Advisors212-915-2577[email protected]
For Media:
Susan RobertsLifeSci Communications202-779-0929[email protected]
SOURCE Nektar Therapeutics